Want to see OMCL full AI Analyst Report?
OMCL Stock Chart & Stats
$38.28
-$0.19(-0.44%)
At close: 4:00 PM EST
$38.28
-$0.19(-0.44%)
Day’s Range― - ―
52-Week Range$27.01 - $55.00
Previous CloseN/A
Volume97.52K
Average Volume (3M)709.61K
Market Cap
$2.09B
Enterprise Value$1.44K
Total Cash (Recent Filing)$290.96M
Total Debt (Recent Filing)$202.18M
Price to Earnings (P/E)103.1
Beta0.56
Next Earnings
Jul 30, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding45,478,910
10 Day Avg. Volume605,668
30 Day Avg. Volume709,606
Financial Highlights & Ratios
PEG Ratio-12.17
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$65.00Price Target Upside69.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.94
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowOmnicell's TTM free cash flow (~$112M, +32%) and operating cash flow (~$156M) build durable internal funding for R&D, platform rollouts and capital allocation. Reliable cash generation reduces refinancing risk and enables investment in OmniSphere/Titan XT without heavy external financing.
Materially Improved LeverageDeleveraging to a ~0.17 debt-to-equity materially lowers financial risk and interest burden, expanding strategic optionality. A cleaner balance sheet supports product development, selective buybacks or M&A, and cushions the company through multi-quarter healthcare capital cycles.
Platform And Product TractionInitial Titan XT orders, planned H2 2026 shipments and OmniSphere platform rollouts (H1 2027) shift mix toward integrated hardware+software. This strengthens differentiation, increases customer stickiness, and supports recurring ARR growth (ARR guidance $680–700M), improving long-term revenue quality.
Bears Say
Very Thin Net MarginsDespite revenue recovery, trailing net margin (~0.2%) and weak ROE show limited earnings power. Thin profitability makes the business vulnerable to cost inflation, tariffs or execution slippage, constraining reinvestment capacity and shareholder returns until margins sustainably expand.
Long Capital Approval CyclesHealth system capital timelines are structural and slow, delaying Titan XT replacements and revenue realization. This leads to lumpy bookings-to-revenue conversion, extends hardware payback periods and increases uncertainty around the timing of material revenue contributions from new products.
Tariff/import Cost PressureAn estimated ~$12M tariff-related cost in 2026 is a recurring regulatory/import risk that erodes gross margins. Tariff volatility can offset margin improvements from operations, complicate multi-year margin planning for hardware-heavy product revenue, and reduce durable profitability.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $27.01 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $2.09B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Apr 28, 2026. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.331 by $0.219.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.47.
How many shares outstanding does Omnicell have?
Omnicell has 45,478,910 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.55 in its last earnings report, beating expectations of $0.331. Following the earnings report the stock price went up 20.941%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.00 (69.80% Upside)
$65.00 (69.80% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 5.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 28.1%
Last 30 Days ▲ 28.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OMCL Stock 12 Month Forecast
Average Price Target
$65.00
▲(69.80% Upside)
Technical Analysis
Ownership Overview
3.01% Insiders
29.49% Mutual Funds
0.55% Other Institutional Investors
34.49% Public Companies and
Individual Investors